Early diagnosis and treatment of chronic kidney disease (CKD) is a worldwide challenge. Albuminuria is defined as urinary albumin:creatinine ratio (ACR) ≥30 mg/g. Subjects with ACR values below this cut-off and preserved renal function are considered at no cardiorenal risk, but increased risk is established even at the 10-30 mg/g ACR range, supporting the need to identify other molecular indicators for early assessment of normoalbuminuric patients at higher risk. Following our previous studies, here we aimed to stratify the normoalbuminuria range according to cardiorenal risk and identify glycoproteins and N-glycosylation sites associated to kidney damage in subclinical CKD.